Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity Group in a research report issued on Tuesday, Benzinga reports.
A number of other analysts have also recently issued reports on the stock. Weiss Ratings cut shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. Oppenheimer reduced their target price on shares of Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. HC Wainwright reiterated a “buy” rating on shares of Connect Biopharma in a research note on Wednesday, October 28th. Wall Street Zen downgraded shares of Connect Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Finally, Leerink Partners started coverage on shares of Connect Biopharma in a research report on Monday, October 12th. They set an “outperform” rating and a $4.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $5.88.
Get Our Latest Report on Connect Biopharma
Connect Biopharma Stock Up 14.9%
Connect Biopharma (NASDAQ:CNTB – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.12 million. As a group, research analysts expect that Connect Biopharma will post -1.09 earnings per share for the current year.
Institutional Investors Weigh In On Connect Biopharma
Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP increased its holdings in shares of Connect Biopharma by 12.0% during the third quarter. Marshall Wace LLP now owns 376,029 shares of the company’s stock worth $414,000 after purchasing an additional 40,387 shares during the period. BML Capital Management LLC raised its position in shares of Connect Biopharma by 574.1% in the third quarter. BML Capital Management LLC now owns 3,864,400 shares of the company’s stock valued at $4,251,000 after buying an additional 3,291,113 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Connect Biopharma in the first quarter valued at approximately $41,000. ADAR1 Capital Management LLC acquired a new stake in shares of Connect Biopharma in the first quarter valued at approximately $1,945,000. Finally, Knott David M Jr boosted its stake in shares of Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after buying an additional 187,835 shares during the period. Institutional investors and hedge funds own 58.72% of the company’s stock.
Connect Biopharma Company Profile
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
Recommended Stories
- Five stocks we like better than Connect Biopharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
